BACKGROUND: Preoperative CT features have demonstrated potential in predicting microvascular invasion (MVI) in hepatocellular carcinoma. These CT signs serve as indicators of tumor biological behavior. However, the molecular mechanisms underlying the ability of CT to preoperatively predict MVI remain largely unexplored. This study aims to elucidate the role of miR-10a-5p in HCC progression and investigate its correlation with specific imaging features. METHODS: According to preoperative CT features, patients were divided into CT-MVI (+) group and CT-MVI (-) group. MiR-10a-5p expression was analyzed in HCC tissues with CT-MVI compared to those without CT-MVI. The functional effects of miR-10a-5p were assessed through in vitro cell viability and apoptosis assays, and in vivo xenograft models. Cell viability was assessed through the CCK8 assay, while flow cytometry was utilized to determine cell apoptosis. The regulatory relationships between miR-10a-5p, CD24, transferrin receptor 1 (TFR1), and STAT3 signaling were explored using western blot, luciferase reporter assays, and rescue experiments. RESULTS: MiR-10a-5p expression was significantly downregulated in HCC tissues with CT-MVI compared to those without CT-MVI. Overexpression of miR-10a-5p reduced cell viability, promoted apoptosis, and inhibited tumor growth in vivo. MiR-10a-5p directly targeted TFR1, leading to decreased CD24 expression and reduced STAT3 phosphorylation. TFR1 overexpression partially rescued the effects of miR-10a-5p on cell apoptosis and CD24 expression. CONCLUSIONS: Our findings reveal miR-10a-5p as a key regulator of HCC progression and MVI, operating through a novel pathway involving TFR1, STAT3, and CD24. This study provides new insights into the molecular mechanisms of CT features and highlights potential therapeutic targets for HCC treatment.
MiR-10a-5p suppresses hepatocellular carcinoma progression and microvascular invasion by targeting TFR1-STAT3-CD24 signaling axis.
miR-10a-5p 通过靶向 TFR1-STAT3-CD24 信号轴抑制肝细胞癌的进展和微血管侵袭。
阅读:5
| 期刊: | Frontiers in Oncology | 影响因子: | 3.300 |
| 时间: | 2025 | 起止号: | 2026 Jan 2; 15:1694441 |
| doi: | 10.3389/fonc.2025.1694441 | 靶点: | CD2、CD24、STAT3、TAT |
| 研究方向: | 细胞生物学 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。